Drug intelligence / Profile preview

HCW11-018

Development stage: Preclinical
Lead developer: HCW Biologics
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

HCW11-018 is a recombinant fusion protein and an immune cell engager developed by HCW Biologics for the treatment of pancreatic and ovarian cancer. It operates through immunologic cytotoxicity and T lymphocyte stimulation.

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on HCW11-018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HCW11-018.

Explore the full profile